Kamada and Chiesi enter into a strategic agreement for the distribution of Kamada's inhaled AAT drug for treatment of Alpha-1 antitrypsin deficiency in Europe, Turkey and former CIS countries.
The trial is testing an innovative breakthrough treatment for Type 1 diabetes, which does not use the only current treatments of insulin and diet. D1-AAT may slow progression of the disease, and may greatly reduce, or completely eliminate, the need for insulin. This will stabilize the condition of diabetics and/or reduce or prevent serious complications of the disease.
Kamada Ltd. (TASE: KMDA) has obtained Food and Drug Administration (FDA) approval to conduct a clinical trial in the US for the company's next generation drug – an inhalable version of AAT (Alpha-1 Antitrypsin deficiency) for the treatment of cystic fibrosis.
This is the second patent issued to Kamada under the same title after being granted with the same patent title by the United States Patent Office (USPTO).
Baxter International Inc. (NYSE: BAX) today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.